Research Article

Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole

Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI 48109-1065, USA

Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI 48109, USA

Department of Internal Medicine, Division of Hematology/Oncology, Medical School, University of Michigan, Ann Arbor, MI 48109, USA

Search for more papers by this author

Andrea M Pesch

Department of Internal Medicine, Division of Hematology/Oncology, Medical School, University of Michigan, Ann Arbor, MI 48109, USA

Search for more papers by this author

Zeruesenay Desta

Department of Medicine, Indiana University, Indianapolis, IN 46202, USA

Search for more papers by this author

Anna Maria Storniolo

Department of Medicine, Indiana University, Indianapolis, IN 46202, USA

Search for more papers by this author

Vered Stearns

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA

Search for more papers by this author

Todd C Skaar

Department of Medicine, Indiana University, Indianapolis, IN 46202, USA

Search for more papers by this author

Daniel F Hayes

Department of Internal Medicine, Division of Hematology/Oncology, Medical School, University of Michigan, Ann Arbor, MI 48109, USA

Search for more papers by this author

N Lynn Henry

Department of Internal Medicine, Division of Hematology/Oncology, Medical School, University of Michigan, Ann Arbor, MI 48109, USA

Search for more papers by this author

James M Rae

Department of Internal Medicine, Division of Hematology/Oncology, Medical School, University of Michigan, Ann Arbor, MI 48109, USA

Search for more papers by this author

Daniel L Hertz

*Author for correspondence: Tel.: +1 734 763 0015; Fax: +1 734 763 4480;

E-mail Address: DLHertz@med.umich.edu

https://orcid.org/0000-0003-0501-1035

Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI 48109-1065, USA

Search for more papers by this author

Published Online:13 Jun 2019https://doi.org/10.2217/pgs-2019-0020

View article

Abstract

Aim: This study tested for associations between SLCO1B1 polymorphisms and circulating estrogen levels in women with breast cancer treated with letrozole or exemestane. Patients & methods: Postmenopausal women with hormone-receptor positive breast cancer were genotyped for SLCO1B1*5 (rs4149056) and rs10841753. Pretreatment and on-treatment plasma estrogens and aromatase inhibitor (AI) concentrations were measured. Regression analyses were performed to test for pharmacogenetic associations with estrogens and drug concentrations. Results:SLCO1B1*5 was associated with elevated pretreatment estrone sulfate and an increased risk of detectable estrone concentrations after 3 months of AI treatment. Conclusion: These findings suggest SLCO1B1 polymorphisms may have an effect on estrogenic response to AI treatment, and therefore may adversely impact the anticancer effectiveness of these agents.

Keywords:

References

1. Howlader N , Altekruse SF , Li CI et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. JNCI J. Natl Cancer Inst. 106(5), pii:dju055 (2014).
Google Scholar
2. Geisler J , Haynes B , Anker G , Dowsett M , Lønning PE . Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J. Clin. Oncol. 20(3), 751–757 (2002).
Medline CASGoogle Scholar
3. Geisler J , King N , Anker G et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients . Clin. Cancer Res. 4(9), 2089–2093 (1998).
Medline CASGoogle Scholar
4. Cuzick J , Sestak I , Baum M et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 11(12), 1135–1141 (2010).
Medline CASGoogle Scholar
5. Regan MM , Neven P , Giobbie-Hurder A et al. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol. 12(12), 1101–1108 (2011).
Medline CASGoogle Scholar
6. Smith I , Yardley D , Burris H et al. Comparative efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor-positive, node-positive early breast cancer: final results of the randomized Phase III femara versus anastrozole clinical evaluation (FACE) trial. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 35(10), 1041–1048 (2017).
Medline CASGoogle Scholar
7. Goss PE , Ingle JN , Pritchard KI et al. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27 – a randomized controlled Phase III trial. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 31(11), 1398–1404 (2013).
Medline CASGoogle Scholar
8. Early Breast Cancer Trialists’ Collaborative Group . Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 386(10001), 1341–1352 (2015).
MedlineGoogle Scholar
9. Miller WR , Larionov AA . Understanding the mechanisms of aromatase inhibitor resistance. Breast Cancer Res. 14(1), 201 (2012).
Medline CASGoogle Scholar
10. Ingle JN , Buzdar AU , Schaid DJ et al. Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer. Cancer Res. 70(8), 3278–3286 (2010).
Medline CASGoogle Scholar
11. Hertz DL , Henry NL , Rae JM . Germline genetic predictors of aromatase inhibitor concentrations, estrogen suppression and drug efficacy and toxicity in breast cancer patients. Pharmacogenomics 18(5), 481–499 (2017).
CASGoogle Scholar
12. Kalliokoski A , Niemi M . Impact of OATP transporters on pharmacokinetics. Br. J. Pharmacol. 158(3), 693–705 (2009).
Medline CASGoogle Scholar
13. Gregory BJ , Chen SM , Murphy MA , Atchley DH , Kamdem LK . Impact of the OATP1B1 c.521T>C single nucleotide polymorphism on the pharmacokinetics of exemestane in healthy postmenopausal female volunteers. J. Clin. Pharm. Ther. 42(5), 547–553 (2017).
Medline CASGoogle Scholar
14. Dudenkov TM , Ingle JN , Buzdar AU et al. SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway . Breast Cancer Res. Treat. 164(1), 189–199 (2017).
Medline CASGoogle Scholar
15. Henry NL , Giles JT , Ang D et al. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res. Treat. 111(2), 365–372 (2008).
Medline CASGoogle Scholar
16. Desta Z , Kreutz Y , Nguyen AT et al. Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age. Clin. Pharmacol. Ther. 90(5), 693–700 (2011).
Medline CASGoogle Scholar
17. Robarge JD , Desta Z , Nguyen AT et al. Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer. Breast Cancer Res. Treat. 161(3), 453–461 (2017).
Medline CASGoogle Scholar
18. Hertz DL , Speth KA , Kidwell KM et al. Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in postmenopausal breast cancer patients. Breast Cancer Res. Treat. 165(3), 659–668 (2017).
Medline CASGoogle Scholar
19. Henry NL , Azzouz F , Desta Z et al. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J. Clin. Oncol. 30(9), 936–942 (2012).
Medline CASGoogle Scholar
20. Pasqualini JR , Chetrite G , Blacker C et al. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. J. Clin. Endocrinol. Metab. 81(4), 1460–1464 (1996).
Medline CASGoogle Scholar
21. Ramsey LB , Moncrieffe H , Smith CN et al. Association of SLCO1B1*14 allele with poor response to methotrexate in juvenile idiopathic arthritis patients. ACR Open Rheumatol. 1, 58–62 (2019).
MedlineGoogle Scholar
22. Wang L , Ellsworth KA , Moon I et al. Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. Cancer Res. 70(1), 319–328 (2010).
Medline CASGoogle Scholar
23. Ghimenti C , Mello-Grand M , Grosso E et al. Regulation of aromatase expression in breast cancer treated with anastrozole neoadjuvant therapy. Exp. Ther. Med. 5(3), 902–906 (2013).
MedlineGoogle Scholar
24. Fuhrman BJ , Schairer C , Gail MH et al. Estrogen metabolism and risk of breast cancer in postmenopausal women. JNCI J. Natl Cancer Inst. 104(4), 326–339 (2012).
CASGoogle Scholar
25. Key T , Appleby P , Barnes I , Reeves G . Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J. Natl Cancer Inst. 94(8), 606–616 (2002).
Medline CASGoogle Scholar
26. Brown SB , Hankinson SE . Endogenous estrogens and the risk of breast, endometrial, and ovarian cancers. Steroids 99, 8–10 (2015).
Medline CASGoogle Scholar
27. Smiley DA , Khalil RA . Estrogenic compounds, estrogen receptors and vascular cell signaling in the aging blood vessels. Curr. Med. Chem. 16(15), 1863–1887 (2009).
Medline CASGoogle Scholar
28. Wang X , Pankratz VS , Fredericksen Z et al. Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Hum. Mol. Genet. 19(14), 2886–2897 (2010).
Medline CASGoogle Scholar
29. Lønning PE . The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum. Ann. Oncol. 22(3), 503–514 (2011).
Medline CASGoogle Scholar
30. Borrie AE , Rose RV , Choi Y-H et al. Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer. Breast Cancer Res. Treat. 172(2), 371–379 (2018).
Medline CASGoogle Scholar
31. Kadakia KC , Kidwell KM , Seewald NJ et al. Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors. Breast Cancer Res. Treat. 164(2), 411–419 (2017).
Medline CASGoogle Scholar
32. Shitara Y . Clinical importance of OATP1B1 and OATP1B3 in drug–drug interactions. Drug Metab. Pharmacokinet. 26(3), 220–227 (2011).
Medline CASGoogle Scholar

Vol. 20, No. 8

Supplemental Materials

Metrics

Downloaded 268 times

History

Received 12 February 2019

Accepted 15 March 2019

Published online 13 June 2019

Published in print June 2019

Information

Keywords

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: https://www.futuremedicine.com/doi/suppl/10.2217/pgs-2019-0020

Acknowledgments

The authors wish to posthumously recognize D Flockhart, who co-chaired the COnsortium on BReast cancer phArmacogomics (COBRA) and passed during preparation of this manuscript.

Financial & competing interests disclosure

This research was supported by Pharmacogenetics Research Network Grant Number U-01 GM61373 David A Flockhart (DAF) and Clinical Pharmacology Training Grant Number 5T32-GM08425 (DAF) from the National Institute of General Medical Sciences, NIH from Grant Numbers M01-RR000042 (University of Michigan), M01-RR00750 (Indiana University) and M01-RR00052 (Johns Hopkins University) from the National Center for Research Resources (NCRR), a component of the NIH, the Breast Cancer Research Foundation (BCRF; N003173 to JM Rae and DF Hayes), the National Cancer Institute (5T32CA083654-12, PI Jeremy Taylor), the National Institute of General Medical Sciences (GM099143 to JM Rae) and the NIH through the University of Michigan’s Cancer Center Support Grant (P30 CA046592) by the use of the following Cancer Center Core: University of Michigan DNA Sequencing Core. In addition, these studies were supported by grants from Pfizer (DF Hayes), Novartis Pharma AG (DF Hayes), the Fashion Footwear Association of New York/QVC Presents Shoes on Sale (DF Hayes). Drugs were supplied by Novartis and Pfizer. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

PDF download